KALARIS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
KALARIS THERAPEUTICS, INC. (KLRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.62 per share for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-11-03
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $6.89, a 78.73% decline year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $32.39.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $13.01.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $3.38.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $24.76, a 79.81% increase from fiscal 2020.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $13.77, a 534.56% increase from fiscal 2019.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $2.17.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2022-09-30 | $5.62 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $6.33 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $6.89 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $24.76 10-K · filed 2022-02-10 | |||
| 2021-09-30 | $25.30 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $25.79 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $32.39 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $13.77 10-K · filed 2022-02-10 | |||
| 2020-09-30 | $13.01 10-Q · filed 2020-11-10 | $12.86 10-Q · filed 2020-11-10 | ||
| 2020-06-30 | $3.38 10-Q · filed 2020-09-02 | $3.30 10-Q · filed 2020-09-02 | ||
| 2019-12-31 | $2.17 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |